List of Excipients in Branded Drug INNOPRAN XL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ANI Pharmaceuticals Inc	INNOPRAN XL	propranolol hydrochloride	62559-590	DIETHYL PHTHALATE
ANI Pharmaceuticals Inc	INNOPRAN XL	propranolol hydrochloride	62559-590	ETHYLCELLULOSE
ANI Pharmaceuticals Inc	INNOPRAN XL	propranolol hydrochloride	62559-590	FERROSOFERRIC OXIDE

Last updated: August 9, 2026

InnoPran XL is an extended-release propranolol hydrochloride capsule whose commercial differentiation depends on controlled release, bedtime dosing, and capsule-based multiparticulate delivery. The strongest excipient opportunities are not simple substitution of one filler or lubricant. They are development programs that preserve the release profile, improve manufacturability, reduce capsule cost, address nitrosamine and allergen controls, and support an abbreviated new drug application (ANDA) with a credible in vitro and in vivo equivalence package.

InnoPran XL Excipient Strategy, Patent Position, and Commercial Opportunities

What is InnoPran XL and how does its formulation work?

InnoPran XL contains propranolol hydrochloride in an extended-release oral capsule. The product is approved in 80 mg and 120 mg strengths and is administered once daily at bedtime. Its formulation uses multiparticulate delivery rather than a conventional single-unit matrix tablet. The product is designed to release propranolol over an extended period after nighttime administration, supporting beta-blocker exposure during the early morning period.

Attribute	InnoPran XL profile
Active ingredient	Propranolol hydrochloride
Dosage form	Extended-release capsule
Strengths	80 mg and 120 mg
Route	Oral
Dosing	Once daily at bedtime
Therapeutic class	Nonselective beta-adrenergic blocker
Reference product status	FDA-approved NDA product
Primary formulation issue	Reproducible extended release from multiparticulate units
Key substitution risk	Changes in polymer grade, coating weight, particle size, or dose loading can alter exposure

The product label identifies inactive ingredients used in the capsule and controlled-release system. Public labeling indicates the use of pellet-based technology with pharmaceutical excipients that can include sugar-based starter cores, coating polymers, hypromellose, ethylcellulose, povidone, talc, and capsule-shell components, depending on the presentation and manufacturing configuration.[1]

The commercial value of the formulation lies in release control, not in the pharmacological novelty of propranolol. Any substitute product must match the reference product’s release behavior across dissolution conditions and demonstrate bioequivalence under FDA requirements for extended-release products.[2]

What excipients are most important in an InnoPran XL formulation?

The most important excipients are the release-controlling polymers and the materials that determine coating uniformity.

Ethylcellulose and other water-insoluble polymers

Ethylcellulose is commonly used as a permeability-controlling coating for multiparticulate dosage forms. Its function is to limit water penetration and drug diffusion. Key variables include:

• Polymer viscosity grade
• Particle size and dispersion
• Plasticizer level
• Coating weight gain
• Pore-former concentration
• Drying conditions
• Coating uniformity across pellet populations

A lower coating weight can accelerate release, while a higher coating weight can delay release and increase the risk of incomplete exposure. Polymer grade changes can affect film permeability even when the nominal coating weight remains constant.

Hypromellose

Hypromellose can function as a film former, binder, pore former, or release-modifying polymer. Its substitution type and viscosity grade affect hydration, film strength, and release rate. Hypromellose is commercially attractive because it is widely available and supported by established compendial and regulatory histories.

The principal development risk is that a formulation team may treat hypromellose as interchangeable across suppliers. Equivalent compendial specifications do not guarantee equivalent performance in a coated multiparticulate system.

Povidone and other binders

Povidone can improve drug adhesion and pellet formation during layering or granulation. Its molecular weight, solution viscosity, and residual moisture can influence pellet strength and coating defects. Excess binder may reduce porosity and change the release curve.

Sugar spheres or other starter cores

Starter-core properties affect drug-layer uniformity and final pellet size distribution. Important attributes include:

• Core diameter distribution
• Friability
• Density
• Surface roughness
• Moisture content
• Mechanical strength

A change in core supplier can alter drug loading, coating surface area, and dissolution. Core substitution therefore requires more than routine incoming-material qualification.

Talc, plasticizers, and pore formers

Talc can reduce tack during coating and improve processing. Plasticizers improve film flexibility and reduce cracking. Water-soluble pore formers can increase permeability in otherwise water-insoluble coatings.

These materials create a formulation-design tradeoff. Higher permeability may improve release consistency but can increase sensitivity to food, alcohol, agitation, and gastrointestinal transit.

Capsule-shell excipients

Capsule shells can contain gelatin or a hypromellose alternative, colorants, titanium dioxide, and other shell-processing materials. Capsule substitution can offer commercial benefits, including:

• Vegetarian or religious-compliance positioning
• Reduced shell brittleness
• Improved machine throughput
• Lower foreign-material risk
• Greater supply-chain resilience

A shell change may still affect moisture transfer into or out of the pellet fill. That effect must be evaluated as part of the complete dosage form.

What formulation characteristics should a generic InnoPran XL developer target?

A generic developer should target the reference product’s critical quality attributes rather than duplicate a proprietary excipient list.

Critical quality attribute	Commercial and regulatory relevance
Assay and content uniformity	Confirms dose consistency between capsules
Pellet size distribution	Affects coating area and release rate
Drug-layer uniformity	Controls dose and early release
Coating weight gain	Primary release-rate variable
Film integrity	Limits dose dumping and batch variability
Dissolution profile	Central to extended-release bioequivalence
Moisture content	Influences polymer permeability and capsule stability
Capsule fill weight	Affects dose uniformity and manufacturing yield
Stability profile	Supports shelf life and packaging selection

The preferred development strategy is a quality-by-design program linking material attributes to dissolution and pharmacokinetic outcomes. A design space can include polymer level, coating weight, plasticizer ratio, pellet size, and curing conditions. Such a design space supports post-approval manufacturing changes and reduces dependence on a single excipient supplier.

What excipient substitutions create the best commercial opportunities?

Polymer-source substitution

The most immediate opportunity is a second-source strategy for ethylcellulose, hypromellose, plasticizers, and pore formers. Drug manufacturers may pay a premium for suppliers that provide:

• Consistent particle-size distribution
• Low residual solvent levels
• Tight viscosity control
• Strong change-control documentation
• Global regulatory support
• Reliable supply during capacity constraints

A supplier that qualifies as an alternate source without changing the release profile can capture value even without developing a new drug product.

Direct-compression or matrix reformulation

A matrix tablet may reduce manufacturing complexity compared with coated pellets. The commercial benefit includes fewer processing steps, lower coating equipment requirements, and potentially lower unit cost.

The regulatory barrier is significant. A matrix tablet would need to demonstrate equivalent release and systemic exposure to the multiparticulate reference product. Matrix systems may also show greater sensitivity to fed and fasted conditions, alcohol exposure, and gastrointestinal hydrodynamics.

Alternative pellet technologies

Fluid-bed layering, extrusion-spheronization, spray drying, and hot-melt approaches can be evaluated as alternatives to the reference manufacturing route. The strongest opportunity is a process that:

1. Produces a narrow pellet-size distribution.
2. Reduces coating time.
3. Improves yield.
4. Limits agglomeration.
5. Maintains dissolution after scale-up.

A process patent may protect a new manufacturing route even when the active ingredient and therapeutic use are established.

Capsule-shell replacement

A hypromellose capsule can create a differentiated product for patients avoiding animal-derived gelatin. The opportunity is commercially narrower than a polymer or process substitution because the shell is not the primary release-controlling component. It may still support institutional procurement and international market access.

Excipient-minimized formulations

A formulation with fewer excipients can reduce material cost and simplify regulatory control. The risk is that removing a pore former, binder, or anti-tacking agent can affect pellet integrity or release uniformity. Excipient reduction is most attractive when it also removes a supply-chain bottleneck or a material associated with patient intolerance.

What patents protect InnoPran XL and its formulation?

InnoPran XL’s relevant intellectual-property categories are likely to include formulation, controlled-release technology, dosing regimen, manufacturing process, and product-specific claims. The active ingredient propranolol hydrochloride is an established compound and does not provide meaningful new-molecule exclusivity for the product.

The FDA Orange Book is the controlling public source for patents submitted by an NDA holder for approved drug products. Patent status can change through delisting, expiration, pediatric extensions, terminal disclaimers, litigation, or corrections.[3]

IP category	Potential scope	Relevance to excipient strategy
Controlled-release formulation	Polymer-coated pellets or multiparticulate release system	Highest risk for close copies
Dosage regimen	Bedtime administration or chronotherapeutic use	Can affect method-of-use exposure
Manufacturing process	Layering, coating, curing, or pellet processing	Relevant to process design-around
Capsule composition	Shell and fill configuration	Usually narrower commercial scope
Product-by-process claims	Defined by manufacturing characteristics	May complicate technical non-infringement analysis
Trademark	InnoPran XL brand	Commercial, not formulation, protection

A company assessing an ANDA opportunity should review the current Orange Book listing, issued patents, patent-family continuity, terminal disclaimers, and any litigation docket. A historical patent that has expired does not eliminate risk from a later-filed formulation or process patent.

When does InnoPran XL lose exclusivity?

The product’s practical exclusivity is determined by several separate dates:

1. New-drug exclusivity under the Federal Food, Drug, and Cosmetic Act.
2. Listed patent expiration dates.
3. Pediatric exclusivity, if granted.
4. Regulatory approval timing for ANDA applicants.
5. Litigation stays triggered by a Paragraph IV notice.
6. Market economics after generic entry.

For an established propranolol extended-release product, the key commercial question is usually no longer chemical exclusivity. It is whether active formulation or method-of-use patents remain enforceable and whether a generic applicant can obtain approval through a Paragraph IV certification or must wait for patent expiry.

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. If the NDA holder initiates litigation within the statutory period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments.[4]

The main generic entry scenarios are:

Scenario	Effect on market entry
No unexpired listed patents	FDA approval can proceed after regulatory review
Paragraph III certification	Approval waits until listed patent expiry
Paragraph IV certification with litigation	Potential 30-month stay
Successful design-around	Reduces infringement exposure but may increase development cost
First substantially complete ANDA with valid Paragraph IV	May qualify for 180-day generic exclusivity
Method-of-use patent only	Product labeling strategy becomes central

A generic developer faces technical risk if its dissolution profile matches the reference product only under limited conditions. FDA may require multiple dissolution media, fed and fasted pharmacokinetic studies, alcohol-dose-dumping assessments, and additional characterization of multiparticulate performance.

What FDA regulatory requirements apply to an InnoPran XL generic?

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence. For an extended-release capsule, the submission generally requires:

• Same active ingredient and dosage form
• Equivalent strength
• Comparable release characteristics
• Stability data
• Manufacturing controls
• Bioequivalence studies
• Labeling consistent with the reference product
• Evaluation of food effects where applicable
• Assessment of alcohol-induced dose dumping where relevant

FDA guidance for extended-release oral dosage forms emphasizes product-specific dissolution and pharmacokinetic evaluation. A formulation that uses different excipients can still be approvable, but the applicant must show that the substitution does not alter safety, efficacy, or bioavailability.[2]

Excipient changes can trigger additional scrutiny when they affect:

• Release rate
• Absorption site
• Food sensitivity
• Dose dumping
• Capsule integrity
• Impurity formation
• Nitrosamine risk
• Pediatric or geriatric tolerability

How strong is the InnoPran XL patent estate?

The patent estate should be considered moderate in technical complexity but weaker at the active-ingredient level because propranolol is off-patent. The principal barriers are formulation replication, bioequivalence, manufacturing scale-up, and any surviving controlled-release or method-of-use claims.

Risk factor	Assessment
Active ingredient patent barrier	Low
Extended-release formulation barrier	Moderate to high
Excipient substitution difficulty	Moderate
Bioequivalence complexity	Moderate to high
Manufacturing scale-up risk	Moderate
Method-of-use patent risk	Requires current Orange Book review
Biosimilar risk	None
Conventional generic competition	High once regulatory barriers clear

The most defensible new IP would cover a distinct release architecture, a validated manufacturing process, a specific excipient ratio linked to performance, or a stability improvement. Broad claims that merely recite propranolol with conventional extended-release polymers may face validity and obviousness challenges.

Which companies are positioned to challenge or compete with InnoPran XL?

Competition can come from four groups:

1. Generic pharmaceutical companies developing propranolol extended-release capsules.
2. Contract development and manufacturing organizations with multiparticulate coating capabilities.
3. Excipient manufacturers supplying controlled-release polymers and starter cores.
4. Competing beta-blocker products, including extended-release metoprolol and other cardiovascular therapies.

Generic competition is likely to focus on manufacturing reliability and contracting access rather than clinical differentiation. The reference product’s bedtime positioning may preserve some brand demand, but payer substitution typically places substantial pressure on pricing after multiple generic entrants.

What revenue exposure and commercial opportunities exist?

InnoPran XL revenue exposure is linked to the size of the propranolol extended-release market, payer substitution, prescription volume, and the number of approved generic suppliers. The product is unlikely to support a premium based solely on the active ingredient. Commercial value is more likely to come from:

• Reliable supply
• Lower manufacturing cost
• Authorized-generic arrangements
• Institutional contracting
• Private-label supply
• International registration
• Capsule-shell differentiation
• Stable performance across multiple excipient sources

For excipient suppliers, the addressable opportunity is broader than the branded product. The same polymer and coating platform can support extended-release products containing other beta-blockers, stimulants, analgesics, and central nervous system compounds.

How does InnoPran XL compare with other extended-release beta-blockers?

Product class	Delivery model	Main formulation challenge	Commercial implication
InnoPran XL	Propranolol multiparticulate extended release	Bedtime release and dissolution matching	Generic development requires detailed release control
Extended-release metoprolol	Matrix or controlled-release tablet	Food effects and dose proportionality	Larger competitive market
Immediate-release propranolol	Conventional tablet or solution	Frequent dosing and tolerability	Lower formulation complexity
Long-acting cardiovascular products	Various	Sustained exposure and adherence	Compete on dosing convenience and clinical familiarity

InnoPran XL’s principal technical distinction is its chronotherapeutic dosing design. A substitute that provides similar total exposure but changes the timing of propranolol release may face regulatory and commercial challenges.

What manufacturing and IP barriers matter most?

The most important manufacturing barriers are coating uniformity, pellet segregation, scale-up, moisture control, and reproducibility between 80 mg and 120 mg strengths. A commercial process should minimize manual intervention and support high capsule-filling throughput.

The most important IP barriers are:

• Claims directed to coated propranolol pellets
• Release profiles defined by dissolution behavior
• Bedtime dosing methods
• Specific polymer combinations
• Manufacturing processes that produce a defined release characteristic
• Patent-family continuations covering alternative strengths or dosage forms

A design-around should begin with claim mapping, not excipient selection. The development team should identify whether a proposed formulation avoids the claimed composition, process, and release limitations while still meeting FDA bioequivalence requirements.

Key Takeaways

• InnoPran XL is a propranolol hydrochloride extended-release capsule in 80 mg and 120 mg strengths.
• Its commercial differentiation is based on multiparticulate release control and bedtime dosing.
• Ethylcellulose, hypromellose, binders, starter cores, plasticizers, and pore formers are the highest-value excipient components.
• The strongest commercial opportunities are alternate polymer sourcing, process optimization, capsule-shell substitution, and generic product development.
• A matrix-tablet reformulation could reduce manufacturing cost but would create substantial bioequivalence and release-profile risk.
• Propranolol’s established status makes formulation, process, and method-of-use patents more important than active-ingredient patents.
• The FDA Orange Book and current patent-family records are required to determine live patent barriers and Paragraph IV exposure.
• Biosimilar risk is not relevant because InnoPran XL is a small-molecule drug.
• Generic entry risk is primarily technical and regulatory once active patent barriers expire or are designed around.

FAQs

Can a generic InnoPran XL use different excipients?

Yes. An ANDA product can use different inactive ingredients if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, stability, and release performance.

Is ethylcellulose essential to an InnoPran XL generic?

No. Ethylcellulose is one possible release-controlling polymer. A different polymer system may be used if it produces equivalent performance and avoids relevant patent claims.

Does InnoPran XL have biosimilar competition?

No. Propranolol is a chemically synthesized small molecule. Competitive products proceed through the generic-drug pathway, not the biosimilar pathway.

Can a company launch an immediate-release propranolol product against InnoPran XL?

An immediate-release product is a different dosage form and would not be an equivalent substitute for the extended-release reference product. Its regulatory pathway and clinical labeling would differ.

What is the highest-value excipient innovation for InnoPran XL?

A polymer or coating system that improves release consistency, reduces coating time, supports multiple suppliers, and maintains bioequivalence offers the strongest combination of regulatory and commercial value.

References

1. DailyMed. (n.d.). InnoPran XL: Propranolol hydrochloride extended-release capsules, prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2003). Guidance for industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. https://www.fda.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulations and Paragraph IV certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submission-requirements